



JC06 Rec'd PCT/PTO 03 OCT 2005

PCT

Law offices of
DODDS & ASSOCIATES

www.doddsassociates.com
E-mail:j.dodds@doddsassociates.com

1707 N. St., NW, Washington DC 20036
Tel:(202)463-3275 Cellular (202) 276-1289 Fax (202) 463-3278

CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited with the U.S. Postal Service first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, 22313-1450 Alexandria on September 29th 2005.


Susanne Somersalo

Certified mail

United States Patent and Trademark Office
Commissioner for Patents
P.O. Box 1450
Alexandria
VA 22323-1450

U.S. Application number 10/530,636
First named applicant: Zavyalov, Vladimir
Atty Docket :Miniferon
International filing date 10/07/2003
Priority date: 10/07/2002
Confirmation no. 9917

Washington D.C. September 29th 2005


RE: Reply to notification to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures

Sir;

This is to reply the notification mailed on 9/19/2005 (copy of the letter is attached). I respectfully submit on behalf of the applicant the corrected Sequence Listing as a paper version and as a computer readable diskette.

The content of the sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter, as required by 37 CFR 1.821 (e), 1.821 (f), 1.821 (g), 1.825 (b), or 1.825(d).

Yours truly;


Leea Susanne Somersalo
L0092

cc. file

enc. Copy of the notification letter
Sequence listing in paper form
Sequence listing in computer readable diskette



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/530,636	Vladimir Petrovich Zavyalov	MINIFERON
INTERNATIONAL APPLICATION NO.		
PCT/FI03/00736		
I.A. FILING DATE	PRIORITY DATE	
10/07/2003	10/07/2002	
CONFIRMATION NO. 9917		
371 FORMALITIES LETTER		
OC000000016996270		

Date Mailed: 09/19/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

MAMIE P PERSON

Telephone: (703) 308-9140 EXT 227

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/530,636	PCT/FI03/00736	MINIFERON

FORM PCT/DO/EO/922 (371 Formalities Notice)



STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/530,636
Source: PCP/10
Date Processed by STIC: 4/13/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05



Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/530,636

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 Wrapped Nucleic
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.

3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5 Variable Length Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7 Skipped Sequences
 (OLD RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8 Skipped Sequences
 (NEW RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11 Use of <220>
 Response Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



PCT

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/530,636

DATE: 04/13/2005
TIME: 16:15:21

Input Set : A:\Miniferon.ST25.txt
Output Set: N:\CRF4\04132005\J530636.raw

3 <110> APPLICANT: Zavyalov, Vladimir
 5 <120> TITLE OF INVENTION: Peptides and recombinant proteins mimicking interferons
 7 <130> FILE REFERENCE: Miniferon
 C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/530,636
 C--> 10 <141> CURRENT FILING DATE: 2005-04-06
 12 <160> NUMBER OF SEQ ID NOS: 4
 14 <170> SOFTWARE: PatentIn version 3.3
 16 <210> SEQ ID NO: 1
 17 <211> LENGTH: 8
 18 <212> TYPE: PRT
 19 <213> ORGANISM: human interferon alfa2
 21 <400> SEQUENCE: 1
 23 Leu Lys Glu Lys Lys Tyr Ser Pro
 24 1 5
 27 <210> SEQ ID NO: 2
 28 <211> LENGTH: 7
 29 <212> TYPE: PRT
 30 <213> ORGANISM: human interferon alfa2
 32 <400> SEQUENCE: 2
 34 Leu Lys Asp Arg His Asp Phe
 35 1 5
 38 <210> SEQ ID NO: 3
 39 <211> LENGTH: 17
 40 <212> TYPE: PRT
 41 <213> ORGANISM: synthetic
 44 <220> FEATURE:
 45 <221> NAME/KEY: PEPTIDE
 46 <222> LOCATION: (1)..(8)
 47 <223> OTHER INFORMATION: peptide sequence from human interferon alfa2 (aa 130-137)
 49 <220> FEATURE:
 50 <221> NAME/KEY: PEPTIDE
 51 <222> LOCATION: (9)..(10)
 52 <223> OTHER INFORMATION: linker
 54 <220> FEATURE:
 55 <221> NAME/KEY: PEPTIDE
 56 <222> LOCATION: (11)..(17)
 57 <223> OTHER INFORMATION: peptide sequence from human interferon alfa2 (aa 30-36)
 59 <400> SEQUENCE: 3
 61 Leu Lys Glu Lys Lys Tyr Ser Pro Ser Ser Leu Lys Asp Arg His Asp
 62 1 5 10 15
 65 Phe
 69 <210> SEQ ID NO: 4
 70 <211> LENGTH: 17

*Does Not Comply
Connected Diskette Needed.*

pp 1-2

*invalid (213) response. See item 10 on Exam
Summary Sheet*

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/530,636

DATE: 04/13/2005
TIME: 16:15:21

Input Set : A:\Miniferon.ST25.txt
Output Set: N:\CRF4\04132005\J530636.raw

71 <212> TYPE: PRT
72 <213> ORGANISM: synthetic
75 <220> FEATURE:
76 <221> NAME/KEY: PEPTIDE
77 <222> LOCATION: (1)..(8)
78 <223> OTHER INFORMATION: peptide sequence from human interferon alfa2 (aa 130-137)
80 <220> FEATURE:
81 <221> NAME/KEY: PEPTIDE
82 <222> LOCATION: (9)..(10)
83 <223> OTHER INFORMATION: linker
84 X is any short chain amino acid
86 <220> FEATURE:
87 <221> NAME/KEY: PEPTIDE
88 <222> LOCATION: (11)..(17)
89 <223> OTHER INFORMATION: peptide sequence from human interferon alfa2 (aa 30-36)
91 <400> SEQUENCE: 4
93 Leu Lys Glu Lys Lys Tyr Ser Pro Xaa Xaa Leu Lys Asp Arg His Asp
94 1 5 10 15
97 Phe

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/530,636

DATE: 04/13/2005
TIME: 16:15:22

Input Set : A:\Miniferon.ST25.txt
Output Set: N:\CRF4\04132005\J530636.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos...9,10

VERIFICATION SUMMARY
PATENT APPLICATION: US/10/530,636

DATE: 04/13/2005
TIME: 16:15:22

Input Set : A:\Miniferon.ST25.txt
Output Set: N:\CRF4\04132005\J530636.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:93 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.